ABT-301
HDAC1/2/3 Inhibitor
Programs
ABT-202
KRAS inhibitors, like other targeted therapies, face the challenge of drug resistance. To address unmet medical needs, Anbogen is developing second-generation KRAS inhibitors to combat resistance mutations. Increasing clinical studies have shown that patients using Sotorasib® and Adagrasib® have developed novel drug resistance mutations, leading to drug resistance.
ABT-202 is a second-generation pan-KRAS inhibitor developed by Anbogens exclusive covalent combination drug design and structural biology design platform.
ABT-501
ABT-501 is an innovative peptide-drug conjugate (PDC) that combines a novel linker-DM1 release functional group with LHRH (luteinizing hormone-releasing hormone) peptide as a targeting small molecule missile. This design effectively delivers the drug to tumors expressing LHRH-R, enhancing anti-tumor efficacy while reducing drug dosage and minimizing the side effects of cancer treatments.
Compared to antibody-drug conjugates (ADCs), PDCs have the advantage of a smaller molecular weight, allowing easier penetration into tumor cells. The synthesis process is simpler and more cost-effective. Additionally, PDCs exhibit excellent safety profiles, with rapid renal clearance, reducing toxicity to the bone marrow and liver.
ABT-501 targets the LHRH receptor, which is overexpressed in approximately 50% of triple-negative breast cancer patients. The target indications for ABT-501 are triple-negative breast cancer and ovarian cancer, where lies a significant market potential.
ABT-101
ABT-101, is an oral, tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients harboring exon 20 insertions (e20i) in HER2, exon20 kinase domain mutation in other solid tumor cancer types, where there’s currently no available treatment for the patients.
ABT-101 demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting HER2 activating mutations (e20i) in HER2.
ABT-301
ABT-301 is a small molecule histone deacetylase inhibitor (HDACi). Cancer cells exhibit higher histone deacetylase activity, which adjusts chromosomal compactness to block the expression of certain tumor suppressor genes. The application of such inhibitors facilitates the expression of tumor suppressor genes, altering the growth, arrest, and differentiation of tumor cells, promoting apoptosis, and ultimately inhibiting tumor growth to achieve cancer treatment.
ABT-301 has demonstrated superior safety in a phase 1 study, opening the door for further clinical development. Data from preclinical studies also indicate that ABT-301 is highly competitive in treating most solid tumors compared to other drugs.
Pipeline
Programs
Indication
Monotherapy / Combination
Pre-clinical
IND-enabling
Phase 1
Phase 2
Phase 3
Clinical Trial
ABT-301
HDAC1/2/3 Inhibitor
Metastatic colorectal cancer
Tislelizumab Bevacizumab
Advanced hepatocellular carcinoma
Immune checkpoint inhibitor
Advanced pancreatic ductal adenocarcinoma
Chemotherapy
ABT-501
LHRH Peptide-drug Conjugate
Triple-negative breast cancer
Monotherapy
ABT-501-COPY
LHRH胜肽-藥物複合體 (DM1)
實體腫瘤(LHRH受體過量表現)
單藥治療
ABT-501-COPY-COPY
LHRH胜肽-藥物複合體 (DM1)
實體腫瘤(LHRH受體過量表現)
單藥治療
ABT-101
HER2 TKI
ABT-202
KRAS Inhibitor
Solid tumors
Monotherapy
Programs
Indication
Metastatic colorectal cancer
Monotherapy / Combination
Tislelizumab Bevacizumab
Pipeline
Phase 2
Clinical Trial
Preparing clinical trial
Indication
Advanced hepatocellular carcinoma
Monotherapy / Combination
Immune checkpoint inhibitor
Pipeline
Pre-clinical
Clinical Trial
Indication
Advanced pancreatic ductal adenocarcinoma
Monotherapy / Combination
Chemotherapy
Pipeline
Pre-clinical
Clinical Trial
Programs
ABT-501
LHRH Peptide-drug Conjugate
Indication
Triple-negative breast cancer
Monotherapy / Combination
Monotherapy
Pipeline
Pre-clinical
Clinical Trial
Programs
ABT-501-COPY
LHRH胜肽-藥物複合體 (DM1)
Indication
實體腫瘤(LHRH受體過量表現)
Monotherapy / Combination
單藥治療
Pipeline
Pre-clinical
Clinical Trial
Programs
ABT-501-COPY-COPY
LHRH胜肽-藥物複合體 (DM1)
Indication
實體腫瘤(LHRH受體過量表現)
Monotherapy / Combination
單藥治療
Pipeline
Pre-clinical
Clinical Trial
Programs
ABT-101
HER2 TKI
Indication
Non-small cell lung cancer
Monotherapy / Combination
Monotherapy
Pipeline
Phase 1
Clinical Trial
NCT05532696
Programs
ABT-202
KRAS Inhibitor
Indication
Solid tumors
Monotherapy / Combination
Monotherapy
Pipeline
Pre-clinical
Clinical Trial
R&D Focus Areas
1
Targets central to well-validated actionable somatic mutations, and epigenetic modification of histone deacetylase inhibition
2
Pursue clinically validated pathways in indications with best-in-class potential
3
Preclinical insights and clinical prove of concept data to drive successful development
4
Anchored in science to transform cancer treatments